THERAPY DOSSIER · th-f07ff226250f

Buspirone

Drug · Serotonin 1a (5-HT1a) receptor partial agonist

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Serotonin 1a (5-HT1a) receptor partial agonist
Target: Serotonin 1a (5-HT1a) receptor
Injury models: Spinal cord injury
Reported indication: Generalised anxiety disorder / anxiety (5-HT1A partial agonist; approved 1986)
First approval: 1986
Development stage: Approved for anxiety; acute-injury (SCI/stroke) use investigational
ChEMBL record: CHEMBL49 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Buspirone; Buspar; Buspirona; BCI-024; Gen-buspirone; Buspirone hydrochloride; APD-405; MJ 9022-1
Note: Not recorded

Clinical trials 10

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04052776 ↗Injury indicationPHASE1completed

Pharmacological Neuromodulation on Leg Motor Activity in Spinal Cord Injury

Spinal Cord Injuries

Enrolment: 3 · Results not recorded

NCT00875836 ↗PHASE4completed

Buspirone Treatment for Marijuana Dependence

Marijuana Dependence

Enrolment: 175 · Results not recorded

NCT06321341 ↗PHASE4recruiting

Vespireit vs Arlevert in Autonomic Dysfunction With Functional Vertigo

Vertigo · Autonomic Dysfunction

Enrolment: 160 · Results not recorded

NCT01123161 ↗PHASE3terminated

Intravenous Thrombolysis and Hypothermia for Acute Ischemic Stroke (ICTuS2/3)

Stroke, Acute

Enrolment: 120 · Results posted

NCT00746954 ↗PHASE3terminated

Buspirone for Recurrent Central Apneas

Central Apnea · Heart Failure

Enrolment: 8 · Results not recorded

NCT05377619 ↗PHASE2completed

Gastric Glitch Treated With Prucalopride and Buspirone (N-of-1)

Dyspepsia

Enrolment: 1 · Results not recorded

NCT00705003 ↗PHASE2completed

Combination BCI-024 (Buspirone) and BCI-049 in Major Depressive Disorder

Major Depressive Disorder

Enrolment: 142 · Results not recorded

NCT03432065 ↗PHASE2withdrawn

Buspirone for Anxiety in Youth with Autism Spectrum Disorders

Autism Spectrum Disorder · Anxiety

Enrolment: 0 · Results not recorded

NCT00840398 ↗PHASE1completed

Relative Bioavailability of 30 mg Buspirone Hydrochloride Tablets

Healthy

Enrolment: 24 · Results not recorded

NCT01843205 ↗PHASE1completed

Buspirone as a Candidate Medication for Methamphetamine Abuse

Methamphetamine Dependence

Enrolment: 9 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29648984 ↗2018Reported benefit

Facilitation of Locomotor Spinal Networks Activity by Buspirone after a Complete Spinal Cord Lesion in Mice.

MouseSpinal cord injuryHemisection / partial

Model: Complete spinal cord transection in mice, including a dual lesion paradigm in animals that had previously recovered from a spinal hemisection

Buspirone acutely increased step number, hindlimb coupling strength and hip angular excursion, and improved paw positioning at contact and paw drag. When combined with training in the dual lesion paradigm it produced long-lasting improvements in paw positioning at contact and paw drag.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…